BTRX-335140BTRX-140是一种研发中的选择性的κ-阿片受体拮抗剂,用于治疗重度抑郁症[1][2][3]截至2020年2月,该药物目前处于2期临床试验中。[2]

BTRX-335140
临床资料
其他名称BTRX-140; CYM-53093
识别信息
  • 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS号2244614-14-8
PubChem CID
ChemSpider
UNII
化学信息
化学式C25H32FN5O2
摩尔质量453.56 g·mol−1
3D模型(JSmol英语JSmol
  • CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
  • InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
  • Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N

参考文献

编辑
  1. ^ BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders. BlackThorn Therapeutics. [2020-01-25]. (原始内容存档于2020-01-25) (英语). 
  2. ^ 2.0 2.1 BTRX 335140 - AdisInsight. adisinsight.springer.com. [2020-01-25]. (原始内容存档于2021-08-31). 
  3. ^ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). J. Med. Chem. February 2019, 62 (4): 1761–1780. PMC 6395531 . PMID 30707578. doi:10.1021/acs.jmedchem.8b01679. 

外部链接

编辑